Clinical implications of serum autotoxin in regular follow up after pediatric living donor liver transplantation for biliary atresia

Ueno, Takehisa; Takase, Koki; Toyama, Chiyoshi; Deguchi, Koichi; Masahata, Kazunori; Nomura, Motonari; Watanabe, Miho; Kamiyama, Masafumi; Tazuke, Yuko; Bessho, Kazuhiko; Okuyama, Hiroomi

doi:https://doi.org/10.1016/j.jpedsurg.2022.02.041

Clinical implications of serum autotoxin in regular follow up after pediatric living donor liver transplantation for biliary atresia

Ueno, Takehisa; Takase, Koki; Toyama, Chiyoshi et al.

Journal of Pediatric Surgery, 2022, 57, 1215-1220

アクセス数:512件（2025-06-10 13:25 集計）

固定URL: https://hdl.handle.net/11094/87646

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日
JPS_2022_3_56	pdf	なし	363 KB	171	2023.07.01
Table1	pdf	なし	367 KB	30	2023.07.01
Table2	pdf	なし	384 KB	29	2023.07.01
Fig.1	jpg	なし	250 KB	13	2023.07.01
Fig.2	jpg	なし	260 KB	13	2023.07.01
Fig.3	jpg	なし	267 KB	15	2023.07.01
Fig.4	jpg	なし	291 KB	16	2023.07.01

Creative Commons : 表示 - 非営利 - 改変禁止

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Clinical implications of serum autotoxin in regular follow up after pediatric living donor liver transplantation for biliary atresia
著者	NRID 1000010456957 1000010456957 ORCID 0000-0002-4639-8814 0000-0002-4639-8814 researchmap permalink ueno-pedsurg ueno-pedsurg Scopus Author ID 21743992300 21743992300 著者名 Ueno, Takehisa
	著者名 Takase, Koki
	NRID 1000010839369 1000010839369 著者名 Toyama, Chiyoshi
	NRID 1000000747082 1000000747082 researchmap permalink deguchi_koichi deguchi_koichi Scopus Author ID 57139781700 57139781700 著者名 Deguchi, Koichi
	NRID 1000040588381 1000040588381 researchmap permalink masahata masahata Scopus Author ID 22938353400 22938353400 著者名 Masahata, Kazunori
	NRID 1000040546909 1000040546909 researchmap permalink moto_pedsurg moto_pedsurg Scopus Author ID 35208741700 35208741700 ORCID 0009-0004-0959-7461 0009-0004-0959-7461 著者名 Nomura, Motonari
	NRID 1000040791728 1000040791728 researchmap permalink miho miho Scopus Author ID 56282966800 56282966800 ORCID 0000-0001-6691-0611 0000-0001-6691-0611 著者名 Watanabe, Miho
	NRID 1000020403074 1000020403074 researchmap permalink kamiyamapedsurg kamiyamapedsurg Scopus Author ID 55559187300 55559187300 著者名 Kamiyama, Masafumi
	NRID 1000010397698 1000010397698 researchmap permalink yukotazuke-osaka yukotazuke-osaka Scopus Author ID 7006109798 7006109798 ORCID 0000-0002-8335-0414 0000-0002-8335-0414 著者名 Tazuke, Yuko
	NRID 1000080423169 1000080423169 著者名 Bessho, Kazuhiko
	NRID 1000030252670 1000030252670 researchmap permalink okuyamahiroomi okuyamahiroomi Scopus Author ID 35496082300 35496082300 ORCID 0000-0002-1347-282X 0000-0002-1347-282X 著者名 Okuyama, Hiroomi
キーワード等	Liver fibrosis
	Cirrhosis
	Liver biopsy
	Liver transplantation
	Fibrosis marker
抄録	Background: : Pediatric patients sometimes develop graft fibrosis after living donor liver transplant (LDLT). Autotaxin is a recently developed serum marker for hepatic fibrosis. We studied the relationship between serum autotaxin levels and histological findings in patients after LDLT for biliary atresia (BA). Methods: Information on patients aged <19 years who received LDLT for BA and were followed for at least 1 year after LDLT was gathered. Autotaxin levels were compared with pathological fibrosis scores. Results: The study included 52 patients, of whom 4 patients had no fibrosis (F0), 36 patients had F1 fibrosis, and 12 patients had F2. The median serum autotaxin level was 0.89 mg/L. In patients with portal vein (PV) complications such as stenosis or thrombosis (n = 7), the mean autotoxin level was 1.25 mg/L compared with 0.95 mg/L in patients without PV complications (p = 0.004). Among patients without PV complications, the mean autotaxin level was 0.90, 0.88, and 1.18 mg/L in F0, F1, and F2 fibrosis, respectively. The mean autotaxin was higher in F2 fibrosis than in F0 or F1 fibrosis (p<0.05). Autotoxin had a high area under the curve (0.86) with the cut-off level of 0.897 mg/L. Conclusion: Serum autotaxin is a novel marker for liver fibrosis in patients after pediatric LDLT for BA. Type of study: : Study of Diagnostic Test. Level of evidence: : Level II.
出版者	Elsevier
収録物名	Journal of Pediatric Surgery
巻(号)	57
ページ	1215-1220
刊行年月	2022-07
言語	英語
ハンドルURL	https://hdl.handle.net/11094/87646
PISSN	00223468
eISSN	15315037
関連情報 (isVersionOf)	DOI (出版社版) https://doi.org/10.1016/j.jpedsurg.2022.02.041
アクセス権	open access
権利情報	© 2022. This manuscript version is made available under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
出版タイプ	Accepted Manuscript
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Journal of Pediatric Surgery. 2022, 57, p. 1215-1220
DC.title	Clinical implications of serum autotoxin in regular follow up after pediatric living donor liver transplantation for biliary atresia
DC.creator	Ueno, Takehisa
	Takase, Koki
	Toyama, Chiyoshi
	Deguchi, Koichi
	Masahata, Kazunori
	Nomura, Motonari
	Watanabe, Miho
	Kamiyama, Masafumi
	Tazuke, Yuko
	Bessho, Kazuhiko
	Okuyama, Hiroomi
DC.publisher	Elsevier
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2022-07
DC.identifier	https://doi.org/10.1016/j.jpedsurg.2022.02.041
DC.subject	Liver fibrosis
	Cirrhosis
	Liver biopsy
	Liver transplantation
	Fibrosis marker
DCTERMS.abstract	Background: : Pediatric patients sometimes develop graft fibrosis after living donor liver transplant (LDLT). Autotaxin is a recently developed serum marker for hepatic fibrosis. We studied the relationship between serum autotaxin levels and histological findings in patients after LDLT for biliary atresia (BA). Methods: Information on patients aged <19 years who received LDLT for BA and were followed for at least 1 year after LDLT was gathered. Autotaxin levels were compared with pathological fibrosis scores. Results: The study included 52 patients, of whom 4 patients had no fibrosis (F0), 36 patients had F1 fibrosis, and 12 patients had F2. The median serum autotaxin level was 0.89 mg/L. In patients with portal vein (PV) complications such as stenosis or thrombosis (n = 7), the mean autotoxin level was 1.25 mg/L compared with 0.95 mg/L in patients without PV complications (p = 0.004). Among patients without PV complications, the mean autotaxin level was 0.90, 0.88, and 1.18 mg/L in F0, F1, and F2 fibrosis, respectively. The mean autotaxin was higher in F2 fibrosis than in F0 or F1 fibrosis (p<0.05). Autotoxin had a high area under the curve (0.86) with the cut-off level of 0.897 mg/L. Conclusion: Serum autotaxin is a novel marker for liver fibrosis in patients after pediatric LDLT for BA. Type of study: : Study of Diagnostic Test. Level of evidence: : Level II.
DC.rights	© 2022. This manuscript version is made available under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
DC.format	87646
citation_title	Clinical implications of serum autotoxin in regular follow up after pediatric living donor liver transplantation for biliary atresia
citation_author	Ueno, Takehisa
	Takase, Koki
	Toyama, Chiyoshi
	Deguchi, Koichi
	Masahata, Kazunori
	Nomura, Motonari
	Watanabe, Miho
	Kamiyama, Masafumi
	Tazuke, Yuko
	Bessho, Kazuhiko
	Okuyama, Hiroomi
citation_publisher	Elsevier
citation_language	英語
citation_date	2022-07
citation_journal_title	Journal of Pediatric Surgery
citation_volume	57
citation_firstpage	1215
citation_lastpage	1220
citation_doi	https://doi.org/10.1016/j.jpedsurg.2022.02.041
citation_public_url	https://hdl.handle.net/11094/87646

Clinical implications of serum autotoxin in regular follow up after pediatric living donor liver transplantation for biliary atresia

閲覧可能ファイル

論文情報

論文詳細を表示